{"organizations": [], "uuid": "38c492bea95c0b847cbd7513638613350f5ec116", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180403.html", "section_title": "Archive News &amp; Video for Tuesday, 03 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-astrazeneca-says-us-fda-approves-b/brief-astrazeneca-says-us-fda-approves-bydureon-for-use-with-basal-insulin-in-patients-with-type-2-diabetes-with-inadequate-glycemic-control-idUSASC09UNZ", "country": "US", "domain_rank": 408, "title": "BRIEF-AstraZeneca Says US FDA Approves BYDUREON For Use With Basal Insulin In Patients With Type 2 Diabetes With Inadequate Glycemic Control", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.012, "site_type": "news", "published": "2018-04-03T20:03:00.000+03:00", "replies_count": 0, "uuid": "38c492bea95c0b847cbd7513638613350f5ec116"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-astrazeneca-says-us-fda-approves-b/brief-astrazeneca-says-us-fda-approves-bydureon-for-use-with-basal-insulin-in-patients-with-type-2-diabetes-with-inadequate-glycemic-control-idUSASC09UNZ", "ord_in_thread": 0, "title": "BRIEF-AstraZeneca Says US FDA Approves BYDUREON For Use With Basal Insulin In Patients With Type 2 Diabetes With Inadequate Glycemic Control", "locations": [], "entities": {"persons": [], "locations": [{"name": "patien", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "neutral"}, {"name": "us fda", "sentiment": "neutral"}, {"name": "astrazeneca plc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 3 (Reuters) - AstraZeneca PLC:\n* US FDA APPROVES BYDUREON FOR USE WITH BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES WITH INADEQUATE GLYCEMIC CONTROL\n* 7 STUDY RESULTS SHOWED SIGNIFICANT HBA1C REDUCTION WHEN BYDUREON WAS ADDED TO INSULIN GLARGINE THERAPY VERSUS INSULIN GLARGINE ALONEâ€‹ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-03T20:03:00.000+03:00", "crawled": "2018-04-04T12:29:50.030+03:00", "highlightTitle": ""}